Blog Read the latest perspectives from our team of subject matter experts and others CEO Insights: Solving Healthcare’s Provider Data Challenge Through H1’s Acquisition of VedaToday, I’m proud to announce that H1 is acquiring Veda. This follows our acquisition of Ribbon Health in December 2024. By bringing in Veda’s suite of products, data, team, and… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact KOL Engagement Patient Representation Provider Data Post Industries:Digital Health Health Plans Pharmaceutical & Biotechnology Drug DevelopmentPatient RepresentationFDA Poised to Make Impact on Underrepresented Populations in Clinical StudiesDiversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. Increasing patient representation in clinical trials not only makes… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationThe Opportunities and Challenges Patient Representation with Expert Daniel PerezThe pursuit of better healthcare for all has many obstacles. Achieving a state where everyone has fair access to healthcare is a massive endeavor with many stakeholders. It requires addressing… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationEthics in Clinical Trials & FDA Guidance PrepClinical trials serve as the bedrock for advancements in medicine, guiding the development of new treatments and therapies. However, a critical issue plaguing these trials is the lack of… Continue reading → Read the articleno Artificial IntelligenceKOL EngagementProvider DataA Holistic Approach to Measuring ImpactMedical Affairs plays an essential role in evidence-based medicine, disease education, and driving better outcomes. Their knowledge is crucial as medications become more specialized and complex. They enable healthcare… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentKOL EngagementPatient RepresentationTrials & Data – H1’s Top 5 Diagnoses (Predictions) for 2024How will AI impact clinical trials? Will FDA legislation improve diversity? What platforms will key opinion leaders adopt? Every year, we take a look at annual predictions to help life… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentSix Possible Implications of Biden’s Executive Order on AI for Life SciencesThe life sciences sector stands on the brink of a new era marked by the confluence of artificial intelligence (AI) and biomedicine. With President Biden’s recent Executive Order on AI,… Continue reading → Read the articleno‹12345›»
